{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:56:22Z","timestamp":1793325382620,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.ijcard.2018.09.043","type":"journal-article","created":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T02:36:32Z","timestamp":1536719792000},"page":"213-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Pulmonary vasodilator therapies are of no benefit in pulmonary hypertension due to left heart disease: A meta-analysis"],"prefix":"10.1016","volume":"273","author":[{"given":"Jacob Y.","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M.","family":"Wales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Cordina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund M.T.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Celermajer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2018.09.043_bb0005","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"Galie","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2018.09.043_bb0010","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jacc.2008.11.051","article-title":"Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study","volume":"53","author":"Lam","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.043_bb0015","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jchf.2013.05.001","article-title":"Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: pulmonary hypertension and heart failure","volume":"1","author":"Miller","year":"2013","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.ijcard.2018.09.043_bb0020","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.110.983866","article-title":"Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study","volume":"124","author":"Guazzi","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.09.043_bb0025","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jacc.2016.05.047","article-title":"Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum","volume":"68","author":"Opitz","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.043_bb0030","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/eurheartj\/ehx700","article-title":"Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial","volume":"39","author":"Bermejo","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2018.09.043_bb0035","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1086\/681264","article-title":"Use of pulmonary arterial hypertension-approved therapy in the treatment of non-group 1 pulmonary hypertension at US referral centers","volume":"5","author":"Trammell","year":"2015","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.ijcard.2018.09.043_bb0040","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0002-8703(97)70105-4","article-title":"A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST)","volume":"134","author":"Califf","year":"1997","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2018.09.043_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.ijcard.2018.09.043_bb0050","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.ijcard.2018.09.043_bb0055","article-title":"Heart failure in 10\u202fyears time: Focus on pharmacological treatment","volume":"88","author":"JJV","year":"2002","journal-title":"Heart"},{"key":"10.1016\/j.ijcard.2018.09.043_bb0060","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/eurjhf\/hfr147","article-title":"Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study","volume":"14","author":"Guazzi","year":"2012","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2018.09.043_bb0065","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1161\/CIRCULATIONAHA.113.001458","article-title":"Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study","volume":"128","author":"Bonderman","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.09.043_bb0070","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1093\/eurheartj\/ehv336","article-title":"Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial","volume":"36","author":"Hoendermis","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2018.09.043_bb0075","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000107791","article-title":"Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension\u2014a multi-center randomized study","volume":"109","author":"Kaluski","year":"2008","journal-title":"Cardiology"},{"key":"10.1016\/j.ijcard.2018.09.043_bb0080","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1161\/CIRCULATIONAHA.107.716373","article-title":"Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension","volume":"116","author":"Lewis","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.09.043_bb0085","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.ahj.2015.03.018","article-title":"PDE 5 inhibition with udenafil improves left ventricular systolic\/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction; a 12-week, randomized, double-blind, placebo-controlled trial","volume":"169","author":"Kim","year":"2015","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2018.09.043_bb0090","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.hlc.2016.09.004","article-title":"Pilot study of endothelin receptor blockade in heart failure with diastolic dysfunction and pulmonary hypertension (BADDHY-Trial)","volume":"26","author":"Koller","year":"2017","journal-title":"Heart Lung Circ."},{"key":"10.1016\/j.ijcard.2018.09.043_bb0095","first-page":"51","article-title":"Macitentan in pulmonary hypertension due to left ventricular dysfunction","author":"Vachiery","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ijcard.2018.09.043_bb0100","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S2213-2600(16)00027-8","article-title":"Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis","volume":"4","author":"Lajoie","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ijcard.2018.09.043_bb0105","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/eurheartj\/ehp022","article-title":"A meta-analysis of randomized controlled trials in pulmonary arterial hypertension","volume":"30","author":"Galie","year":"2009","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2018.09.043_bb0110","doi-asserted-by":"crossref","first-page":"D100","DOI":"10.1016\/j.jacc.2013.10.033","article-title":"Pulmonary hypertension due to left heart diseases","volume":"62","author":"Vachiery","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.043_bb0115","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1161\/01.CIR.85.2.504","article-title":"Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure","volume":"85","author":"Cody","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.09.043_bb0120","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1161\/01.CIR.98.21.2262","article-title":"Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure","volume":"98","author":"Sutsch","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.09.043_bb0125","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jchf.2017.02.021","article-title":"Long-term effect of endothelin receptor antagonism with bosentan on the morbidity and mortality of patients with severe chronic heart failure: primary results of the ENABLE trials","volume":"5","author":"Packer","year":"2017","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.ijcard.2018.09.043_bb0130","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1161\/CIRCHEARTFAILURE.108.802116","article-title":"Clinical use of phosphodiesterase-5 inhibitors in chronic heart failure","volume":"1","author":"Guazzi","year":"2008","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.ijcard.2018.09.043_bb0135","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1054\/jcaf.2001.25652","article-title":"Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure","volume":"7","author":"Packer","year":"2001","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.ijcard.2018.09.043_bb0140","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/eurheartj\/ehw593","article-title":"Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study","volume":"38","author":"Pieske","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2018.09.043_bb0145","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.2015.15734","article-title":"Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial","volume":"314","author":"Gheorghiade","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2018.09.043_bb0150","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/0735-1097(95)00587-0","article-title":"Transplant candidates with severe left ventricular dysfunction managed with medical treatment: characteristics and survival","volume":"27","author":"Rickenbacher","year":"1996","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.09.043_bb0155","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/ejhf.1067","article-title":"Haemodynamic effects of an acute vasodilator challenge in heart failure patients with reduced ejection fraction and different forms of post-capillary pulmonary hypertension","volume":"20","author":"Ghio","year":"2018","journal-title":"Eur. J. Heart Fail."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527318343717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527318343717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T09:23:00Z","timestamp":1545902580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527318343717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":31,"alternative-id":["S0167527318343717"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2018.09.043","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pulmonary vasodilator therapies are of no benefit in pulmonary hypertension due to left heart disease: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2018.09.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}